Tarsus Pharmaceuticals, Inc. Common Stock TARS
$71.03
+0.59%
at last close
Analyst Consensus
- Consensus Rating
- Buy (5 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $95.00
- Implied Upside
- +33.7%
- Price Target Range
- $88.00 – $100.00
- Analysts (12 mo)
- 5
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-12 | OppenheimerFrancois Brisebois |
Maintains | Outperform | $97 → $100 |
| 2026-07-31 | MizuhoGraig Suvannavejh |
Maintains | Outperform | $100 → $98 |
| 2026-07-21 | GuggenheimBrad Canino |
Maintains | Buy | $90 → $89 |
| 2026-07-09 | HC Wainwright & Co.Matthew Caufield |
Reiterates | Buy | $88 |
| 2026-05-04 | HC Wainwright & Co.Matthew Caufield |
Reiterates | Buy | $88 |
| 2026-02-25 | OppenheimerFrancois Brisebois |
Maintains | Outperform | $95 → $105 |
| 2026-02-25 | GuggenheimEddie Hickman |
Maintains | Buy | $87 → $90 |
| 2025-12-09 | BarclaysGlen Santangelo |
Initiates coverage on | Overweight | $100 |
| 2025-11-20 | MizuhoGraig Suvannavejh |
Initiates coverage on | Outperform | $100 |
| 2025-11-05 | GuggenheimEddie Hickman |
Maintains | Buy | $84 → $87 |
| 2025-10-20 | HC Wainwright & Co.Matthew Caufield |
Maintains | Buy | $72 → $88 |
| 2025-05-27 | HC Wainwright & Co.Matthew Caufield |
Assumes | Buy | $72 |
| 2025-05-05 | Goldman SachsAndrea Tan |
Maintains | Neutral | $46 → $51 |
| 2025-05-02 | GuggenheimEddie Hickman |
Maintains | Buy | $78 → $84 |
| 2025-03-06 | JefferiesAnthony Petrone |
Maintains | Buy | $54 → $58 |
| 2025-02-26 | GuggenheimEddie Hickman |
Maintains | Buy | $75 → $78 |
| 2025-02-26 | HC Wainwright & Co.Oren Livnat |
Reiterates | Buy | $73 |
| 2025-02-26 | BarclaysBalaji Prasad |
Maintains | Overweight | $62 → $60 |
| 2025-02-24 | GuggenheimEddie Hickman |
Reiterates | Buy | — |
| 2025-02-10 | GuggenheimEddie Hickman |
Reiterates | Buy | — |
| 2025-01-27 | BarclaysBalaji Prasad |
Maintains | Overweight | $60 → $62 |
| 2025-01-22 | OppenheimerFrancois Brisebois |
Maintains | Outperform | $65 → $72 |
| 2024-11-15 | Goldman SachsAndrea Tan |
Maintains | Neutral | $36 → $41 |
| 2024-11-14 | OppenheimerFrancois Brisebois |
Maintains | Outperform | $63 → $65 |
| 2024-08-09 | OppenheimerFrancois Brisebois |
Reiterates | Outperform | $61 → $63 |
| 2024-05-13 | HC Wainwright & Co.Oren Livnat |
Maintains | Buy | $57 → $61 |
| 2024-05-10 | BarclaysBalaji Prasad |
Maintains | Overweight | $50 → $60 |
| 2024-05-09 | OppenheimerFrancois Brisebois |
Maintains | Outperform | $59 → $61 |
| 2024-03-06 | JefferiesAnthony Petrone |
Maintains | Buy | $30 → $44 |
| 2024-02-29 | Goldman SachsAndrea Tan |
Maintains | Neutral | $19 → $30 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $71.03
- Market Cap
- $3.10 billion
- 52-Week Range
- $38.51 – $85.25
- Average Volume
- 1.03 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.